Integrated biotechnology platform for biomass valorization and precision cell engineering

Background

The biomass processing and biomedical research sectors face significant challenges that span from sustainable material utilization to precise disease modeling. In the pulp and paper industry, lignin—a major aromatic polymer—remains largely burned for energy despite its potential as a renewable feedstock for chemicals and materials. Likewise, cancer research into DNA polymerase ε (POLE) mutations struggles with incomplete understanding of mutation signatures and repair pathways that drive tumor evolution. At the same time, studies of gene-specific effects in human cells are hampered by the lack of standardized, genetically defined model systems. Together, these gaps highlight an urgent need for technologies that can valorize industrial byproducts, unravel complex mutational processes, and enable reproducible cellular assays.

Current approaches are hindered by several shortcomings. Lignin must typically be isolated and purified before modification, a process that is energy-intensive and yields heterogeneous material with low reactivity. Investigations of POLE-driven mutagenesis rely on tumor samples with variable genetic backgrounds and inconsistent mismatch repair status, limiting the reproducibility of mutation signature data. Finally, conventional cell lines lack engineered point mutations in key polymerase genes, forcing researchers to depend on patient-derived specimens that vary in mutation load and phenotypic stability. These obstacles restrict throughput, increase costs, and slow progress across these interrelated fields.

Technology

This technology combines a streamlined chemical process for upgrading lignin with engineered biological systems for studying cancer-associated mutations. In one arm, kraft black liquor is directly phenolated by condensing phenol in acidic or alkaline media, using either a 160 °C oil bath for two hours or a 190 °C microwave treatment for 15 minutes. This in situ approach triples the phenolic hydroxyl content from ≈2 mmol/g to ≈6.5 mmol/g, as quantified by 31P NMR and characterized by gel permeation chromatography. In parallel, CRISPR/Cas9 is used to generate human cell lines harboring precise POLE and POLD1 point mutations, enabling whole-exome sequencing to unravel mutation signatures in mismatch repair–proficient and –deficient contexts. These cell lines serve as reproducible platforms for mechanistic studies and assay development.

What sets this technology apart is its integration with existing pulp recovery streams and its rapid, energy-efficient microwave-assisted phenolation that eliminates lignin isolation. The engineered cell models are the first to carry defined cancer-linked polymerase mutations, offering unprecedented clarity on POLE-driven mutagenesis even in the presence of functional repair. Together, these advances deliver a unified toolkit for sustainable materials valorization and high-resolution cancer genetics research.

Benefits

• In situ phenolation of lignin directly in black liquor increases phenolic OH content over threefold, converting a low-value byproduct into reactive, value-added biopolymers
• Integration with existing pulp and paper recovery processes and microwave-assisted heating enables rapid, energy-efficient lignin modification
• Quantitative 31P NMR and GPC analysis (with planned 2D HSQC NMR) ensures precise control over lignin reactivity and molecular characteristics
• CRISPR/Cas9-engineered human cell lines harboring defined POLE/POLD1 mutations provide precise models for studying tumor mutagenesis and mismatch-repair interactions
• Comprehensive mutation signature profiling from engineered cells and TCGA data informs cancer diagnostics, prognostics, and the development of targeted therapies
• Standardized, commercially available cell line platforms accelerate SNP assay development and broader biomedical research applications

Applications

• Bio-based phenolic resin production
• Sustainable adhesive manufacturing
• Eco-friendly plastic precursor development
• Cancer mutation diagnostic assays
• CRISPR-engineered cell line supply

Additional info

Innovative processes enable in situ phenolation of kraft lignin in black liquor using acid or base‐catalyzed condensation with phenol (1:1–1:3) at 160 °C/2 h or 190 °C/15 min microwave heating, tripling phenolic OH content (³¹P NMR) and preserving molecular weight (GPC); CRISPR/Cas9-engineered human cell lines harboring POLE/POLD1 cancer-associated mutations allow signature-specific mutagenesis profiling via WES, facilitating studies of mutational burdens, mismatch repair interactions, and assay development for diagnostics.